
Muthusamy Kunnimalaiyaan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8958550/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer. Surgery, 2020, 167, 73-79.	1.9	31
2	Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines. PLoS ONE, 2019, 14, e0213776.	2.5	19
3	Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro. BMC Cancer, 2018, 18, 560.	2.6	33
4	Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines. American Journal of Surgery, 2017, 213, 645-651.	1.8	9
5	Antiproliferative and apoptotic effects of xanthohumol in cholangiocarcinoma. Oncotarget, 2017, 8, 88069-88078.	1.8	19
6	Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. American Journal of Surgery, 2016, 211, 755-760.	1.8	7
7	Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. Hpb, 2015, 17, 770-776.	0.3	27
8	Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2015, 16, 29-37.	1.7	16
9	Xanthohumol Inhibits Notch Signaling and Induces Apoptosis in Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0127464.	2.5	46
10	Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. Cancer Cell International, 2015, 15, 13.	4.1	23
11	Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. Journal of Surgical Research, 2015, 198, 434-440.	1.6	25
12	Notch signaling in hepatocellular carcinoma: molecular targeting in an advanced disease. Hepatoma Research, 2015, 1, 11.	1.5	10
13	Xanthohumol-Mediated Suppression of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 1395-1403.	4.1	44
14	Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biology and Therapy, 2014, 15, 510-515.	3.4	34
15	MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. Journal of Surgical Research, 2014, 191, 280-285.	1.6	21
16	MK-2206 Causes Growth Suppression and Reduces Neuroendocrine Tumor Marker Production in Medullary Thyroid Cancer Through Akt Inhibition. Annals of Surgical Oncology, 2013, 20, 3862-3868.	1.5	8
17	Leflunomide suppresses growth in human medullary thyroid cancer cells. Journal of Surgical Research, 2013, 185, 212-216.	1.6	22
18	Synergistic Effect of Pasireotide and Teriflunomide in Carcinoids in vitro. Neuroendocrinology, 2013, 97, 183-192.	2.5	10

#	Article	IF	CITATIONS
19	Mitochondria-targeted antioxidant and glycolysis inhibition. Anti-Cancer Drugs, 2013, 24, 881-888.	1.4	29
20	Resveratrol Induces Differentiation Markers Expression in Anaplastic Thyroid Carcinoma via Activation of Notch1 Signaling and Suppresses Cell Growth. Molecular Cancer Therapeutics, 2013, 12, 1276-1287.	4.1	93
21	Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anti-Cancer Drugs, 2013, 24, 66-72.	1.4	19
22	Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale, 2012, 4, 7185.	5.6	104
23	Chrysin induces growth suppression through apoptosis in neuroblastoma cells. Journal of the American College of Surgeons, 2012, 215, S70.	0.5	3
24	Abstract 951: Preclinical evaluation of Xanthohumol in carcinoid cancer growth in vitro and in vivo. , 2012, , .		0
25	The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors. Global Journal of Biochemistry, 2012, 3, .	0.5	1
26	Hesperetin, a potential therapy for carcinoid cancer. American Journal of Surgery, 2011, 201, 329-333.	1.8	52
27	Expression of the Active Notch1 Decreases MTC Tumor Growth In Vivo. Journal of Surgical Research, 2011, 171, 23-27.	1.6	22
28	Antiproliferative Effect of Chrysin on Anaplastic Thyroid Cancer. Journal of Surgical Research, 2011, 170, 84-88.	1.6	47
29	Resveratrol Induces Notch2-Mediated Apoptosis and Suppression of Neuroendocrine Markers in Medullary Thyroid Cancer. Annals of Surgical Oncology, 2011, 18, 1506-1511.	1.5	49
30	Identification and validation of Notch pathway activating compounds through a novel highâ€ŧhroughput screening method. Cancer, 2011, 117, 1386-1398.	4.1	49
31	Abstract 2181: Tumor suppressor role of Notch3 in medullary thyroid carcinoma. , 2011, , .		0
32	Notch 1 signaling is active in ovarian cancer. Gynecologic Oncology, 2010, 117, 130-133.	1.4	89
33	Focal Adhesion Kinase, a Downstream Mediator of Raf-1 Signaling, Suppresses Cellular Adhesion, Migration, and Neuroendocrine Markers in BON Carcinoid Cells. Molecular Cancer Research, 2010, 8, 775-782.	3.4	12
34	Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth. Molecular Cancer Therapeutics, 2010, 9, 429-437.	4.1	31
35	Inhibition of Growth in Medullary Thyroid Cancer Cells with Histone Deacetylase Inhibitors and Lithium Chloride. Journal of Surgical Research, 2010, 159, 640-644.	1.6	34
36	MG-132 Inhibits Carcinoid Growth and Alters the Neuroendocrine Phenotype. Journal of Surgical Research, 2010, 158, 15-19.	1.6	13

#	Article	IF	CITATIONS
37	ZM336372 Induces Apoptosis Associated with Phosphorylation of GSK-3β in Pancreatic Adenocarcinoma Cell Lines. Journal of Surgical Research, 2010, 161, 28-32.	1.6	7
38	Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer. American Journal of Surgery, 2010, 199, 315-318.	1.8	24
39	Abstract 4142: The effects of SBHA on Notch 1 expression and platinum sensitivity in ovarian cancer cells. , 2010, , .		0
40	Abstract 3085: Overexpression of theNOTCH3intracellular domain alters neuroendocrine phenotype in carcinoid tumor cells. , 2010, , .		0
41	Lithium inhibits carcinoid cell growth in vitro. American Journal of Translational Research (discontinued), 2010, 2, 248-53.	0.0	17
42	Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. International Journal of Clinical and Experimental Medicine, 2010, 3, 95-102.	1.3	26
43	Medullary Thyroid Carcinoma: Targeted Therapies and Future Directions. Journal of Oncology, 2009, 2009, 2009, 1-7.	1.3	11
44	Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-31². Molecular Cancer Therapeutics, 2009, 8, 914-920.	4.1	39
45	Phosphatidylinositol 3-Kinase-Akt Signaling in Pulmonary Carcinoid Cells. Journal of the American College of Surgeons, 2009, 209, 82-88.	0.5	25
46	Teriflunomide activates the Notch pathway and leads to carcinoid cancer growth suppression by cell cycle arrest. Journal of the American College of Surgeons, 2009, 209, S34.	0.5	0
47	Resveratrol regulates the Notch2-mediated neuroendocrine phenotype in human carcinoid cancer cells. Journal of the American College of Surgeons, 2009, 209, S126.	0.5	Ο
48	Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells. World Journal of Surgery, 2009, 33, 2452-2457.	1.6	10
49	Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies. Journal of Ovarian Research, 2009, 2, 8.	3.0	18
50	Combination Therapy with Histone Deacetylase Inhibitors and Lithium Chloride: A Novel Treatment for Carcinoid Tumors. Annals of Surgical Oncology, 2009, 16, 481-486.	1.5	35
51	Inhibition of Phosphatidylinositol 3-Kinase/Akt Signaling Suppresses Tumor Cell Proliferation and Neuroendocrine Marker Expression in GI Carcinoid Tumors. Annals of Surgical Oncology, 2009, 16, 2936-2942.	1.5	31
52	Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. American Journal of Surgery, 2009, 197, 313-319.	1.8	13
53	AKT and PTEN expression in human gastrointestinal carcinoid tumors. American Journal of Translational Research (discontinued), 2009, 1, 291-9.	0.0	13
54	ZM336372, A Raf-1 Activator, Causes Suppression of Proliferation in a Human Hepatocellular Carcinoma Cell Line. Journal of Gastrointestinal Surgery, 2008, 12, 852-857.	1.7	7

#	Article	IF	CITATIONS
55	Suberoyl Bishydroxamic Acid Activates Notch1 Signaling and Suppresses Tumor Progression in an Animal Model of Medullary Thyroid Carcinoma. Annals of Surgical Oncology, 2008, 15, 2600-2605.	1.5	31
56	PI3K-Akt signaling in pulmonary carcinoid cells. Journal of the American College of Surgeons, 2008, 207, S31.	0.5	0
57	Tautomycetin suppresses carcinoid tumor growth and bioactive hormone production through inactivation of glycogen synthase kinase-3 beta. Journal of the American College of Surgeons, 2008, 207, S103-S104.	0.5	0
58	Regulation of cell–cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway. Surgery, 2008, 144, 920-925.	1.9	12
59	Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery, 2008, 144, 956-962.	1.9	46
60	Valproic Acid Induces Notch1 Signaling in Small Cell Lung Cancer Cells. Journal of Surgical Research, 2008, 148, 31-37.	1.6	62
61	Suberoyl Bis-Hydroxamic Acid Activates Notch-1 Signaling and Induces Apoptosis in Medullary Thyroid Carcinoma Cells. Oncologist, 2008, 13, 98-104.	3.7	54
62	Current Management of Medullary Thyroid Cancer. Oncologist, 2008, 13, 539-547.	3.7	155
63	Valproic Acid Activates Notch1 Signaling and Induces Apoptosis in Medullary Thyroid Cancer Cells. Annals of Surgery, 2008, 247, 1036-1040.	4.2	71
64	Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. Current Opinion in Investigational Drugs, 2008, 9, 576-82.	2.3	16
65	Valproic Acid Activates Notch-1 Signaling and Regulates the Neuroendocrine Phenotype in Carcinoid Cancer Cells. Oncologist, 2007, 12, 942-951.	3.7	131
66	Tumor Suppressor Role of Notchâ€l Signaling in Neuroendocrine Tumors. Oncologist, 2007, 12, 535-542.	3.7	175
67	Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Molecular Cancer Therapeutics, 2007, 6, 1151-1158.	4.1	100
68	Raf-1 activation in gastrointestinal carcinoid cells decreases tumor cell adhesion. American Journal of Surgery, 2007, 193, 331-335.	1.8	8
69	The HDAC Inhibitor Trichostatin A Inhibits Growth of Small Cell Lung Cancer Cells. Journal of Surgical Research, 2007, 142, 219-226.	1.6	86
70	Suberoylanilide hydroxamic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Journal of the American College of Surgeons, 2007, 205, S90.	0.5	0
71	Lithium ions: A novel treatment for pheochromocytomas and paragangliomas. Surgery, 2007, 141, 161-165.	1.9	25
72	Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways. Surgery, 2007, 142, 959-964.	1.9	18

#	Article	IF	CITATIONS
73	Suberoyl Bishydroxamic Acid Inhibits Cellular Proliferation by Inducing Cell Cycle Arrest in Carcinoid Cancer Cells. Journal of Gastrointestinal Surgery, 2007, 11, 1515-1520.	1.7	26
74	Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells. Translational Oncogenomics, 2007, 2, 43-7.	1.7	4
75	Overexpression of the NOTCH1 Intracellular Domain Inhibits Cell Proliferation and Alters the Neuroendocrine Phenotype of Medullary Thyroid Cancer Cells. Journal of Biological Chemistry, 2006, 281, 39819-39830.	3.4	114
76	ZM336372, A Raf-1 Activator, Inhibits Growth of Pheochromocytoma Cells. Journal of Surgical Research, 2006, 133, 42-45.	1.6	21
77	In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anti-Cancer Drugs, 2006, 17, 849-853.	1.4	23
78	The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?. Anti-Cancer Drugs, 2006, 17, 139-142.	1.4	43
79	Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery, 2006, 140, 1009-1015.	1.9	67
80	Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery, 2005, 138, 1137-1142.	1.9	50
81	Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. American Journal of Physiology - Renal Physiology, 2005, 289, G636-G642.	3.4	76
82	Regulation of Neuroendocrine Differentiation in Gastrointestinal Carcinoid Tumor Cells by Notch Signaling. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4350-4356.	3.6	102
83	ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Molecular Cancer Therapeutics, 2005, 4, 910-917.	4.1	72
84	Molecular Characterization of Plasmid pBM300 from Bacillus megaterium QM B1551. Applied and Environmental Microbiology, 2005, 71, 3068-3076.	3.1	14
85	Medullary Thyroid Cancer: The Functions of raf-1 and Human Achaete-scute Homologue-1. Thyroid, 2005, 15, 511-521.	4.5	43
86	A Mouse Model of Carcinoid Syndrome and Heart Disease. Journal of Surgical Research, 2005, 126, 102-105.	1.6	30
87	A mouse model of carcinoid syndrome and heart disease. Journal of the American College of Surgeons, 2004, 199, 17.	0.5	0
88	Required sequence elements for chloroplast DNA replication activity in vitro and in electroporated chloroplasts. Plant Science, 2004, 166, 151-161.	3.6	18
89	The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery, 2003, 134, 866-871.	1.9	57
90	Sequencing and Characterization of pBM400 from Bacillus megaterium QM B1551. Applied and Environmental Microbiology, 2003, 69, 6888-6898.	3.1	23

#	Article	IF	CITATIONS
91	Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. American Journal of Physiology - Renal Physiology, 2003, 285, G245-G254.	3.4	83
92	Analysis of the replicon region and identification of an rRNA operon on pBM400 of Bacillus megaterium QM B1551. Molecular Microbiology, 2001, 39, 1010-1021.	2.5	36
93	Characterization of a Theta Plasmid Replicon with Homology to All Four Large Plasmids ofBacillus megateriumQM B1551. Plasmid, 1998, 40, 175-189.	1.4	16
94	In vitro replication of mitochondrial plasmid mp1 from the higher plant Chenopodium album (L.): a remnant of bacterial rolling circle and conjugative plasmids?. Journal of Molecular Biology, 1998, 284, 1005-1015.	4.2	13
95	Analysis of the tobacco chloroplast DNA replication origin (ori B) downstream of the 23 S rRNA gene 1 1Edited by N. H. Chua. Journal of Molecular Biology, 1997, 268, 273-283.	4.2	26
96	Chloroplast DNA Replication : Mechanism, Enzymes and Replication Origins. Journal of Plant Biochemistry and Biotechnology, 1997, 6, 1-7.	1.7	32
97	Characterization of replication origins flanking the 23S rRNA gene in tobacco chloroplast DNA. Plant Molecular Biology, 1996, 32, 693-706.	3.9	27